BridgeBio Pharma
BBIO
161 hedge funds and large institutions have $8.61B invested in BridgeBio Pharma in 2020 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 64 increasing their positions, 37 reducing their positions, and 11 closing their positions.
291% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 11
229% more call options, than puts
Call options by funds: $27.7M | Put options by funds: $8.42M
96% more capital invested
Capital invested by funds: $4.39B → $8.61B (+$4.22B)
73% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 37
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
25% more funds holding
Funds holding: 129 → 161 (+32)
2.37% more ownership
Funds ownership: 96.31% → 98.68% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rockefeller Capital Management
New York
|
+$37.5M |
| 2 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$26.3M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$22.2M |
| 4 |
BlackRock
New York
|
+$19.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIG
American International Group
New York
|
-$110M |
| 2 |
Citigroup
New York
|
-$8.98M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$5.94M |
| 4 |
AG
Artal Group
Luxembourg
|
-$4.82M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$3.35M |
BBIO Hedge Fund Activity: Q4 2020 in Review
161 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2020, worth a combined $8.61B — up 96% from $4.39B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new BBIO positions and 11 closed out — a net gain of 32 holders — while 64 added to existing stakes and 37 trimmed.
The largest buyer was Rockefeller Capital Management, opening a new position worth an estimated $37.5M. The largest seller was American International Group, cutting an estimated $110M.
- 161 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2020, up from 129 in Q3 2020.
- Funds reported $8.61B of BridgeBio Pharma stock for Q4 2020, up 96% quarter-over-quarter.
- 43 funds opened new BridgeBio Pharma positions in Q4 2020 and 11 closed out, a net change of +32 holders.
- The largest BridgeBio Pharma buyer in Q4 2020 was Rockefeller Capital Management, an estimated $37.5M added.
- The largest BridgeBio Pharma seller in Q4 2020 was American International Group, an estimated $110M sold.
Based on aggregated 13F filings for Q4 2020.